Cangene

Cangene reports $28.7 million in revenues

Published in Lab Business Week, July 16th, 2006

Cangene reported results for the third quarter and 9 months ended April 30, 2006.

Revenue for the third quarter of fiscal 2006 was $28.7 million, an increase of $2.0 million or 7.7% compared to the same quarter of the prior year.

Revenue for the 9 months ended April 30, 2006 was $82.6 million, also up $2.0 million over same period a year ago. Revenue for the quarter increased due to completion of delivery on the U.K.-government order for Vaccinia immune globulin ("VIG"), and stronger WinRho SDF sales in the U.S. following the transition in distributors from Nabi Biopharmaceuticals to Baxter Healthcare Corp. Sales of WinRho SDF in the U.S. improved...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-07-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry